Pharmaceutical - Depomed

Filter

Current filters:

Depomed

Popular Filters

Mallinckrodt’s MNK-155 shows efficacy in Ph III acute pain trial

Mallinckrodt’s MNK-155 shows efficacy in Ph III acute pain trial

05-09-2014

US drugmaker Mallinckrodt reported that a Phase III efficacy trial of investigational MNK-155 met the…

AcuformDepomedMallinckrodtMNK-155NeurologicalPharmaceuticalResearch

Depomed prevails in Gralise ANDA litigation with Actavis

Depomed prevails in Gralise ANDA litigation with Actavis

20-08-2014

US drug maker Depomed saw its shares climb more than 12% to $14.76 on Tuesday, on the news that the firm…

ActavisDepomedGraliseLegalNeurologicalPatentsPharmaceuticalUSA

Mallinckrodt gains FDA approval for Xartemis XR

Mallinckrodt gains FDA approval for Xartemis XR

12-03-2014

The US Food and Drug Administration has approved Ireland-headquartered specially drugmaker Mallinckrodt’s…

DepomedMallinckrodtNeurologicalNorth AmericaPharmaceuticalRegulationUSAXartemis XR

PDL BioPharma secures royalties on diabetes products in $240m deal

PDL BioPharma secures royalties on diabetes products in $240m deal

22-10-2013

PDL BioPharma has acquired the rights to receive royalties and milestones payable on sales of Type 2…

DepomedDiabetesFinancialGlumetzaInvokanaJanumetLicensingmetforminNorth AmericaPDL BioPharmaPharmaceutical

Depomed expands geographic scope of metformin deal with Merck

10-09-2013

USA-based Depomed (Nasdaq: DEPO) says it has expanded the geographic scope of its non-exclusive license…

DepomedDiabetesJanumetLicensingMerck & CometforminPharmaceutical

US FDA grants priority review for Mallinckrodt's pain relief drug

29-07-2013

The US Food and Drug Administration has accepted and granted a priority review for the New Drug Application…

DepomedMallinckrodtNorth AmericaOxycodone and AcetaminophenPharmaceuticalRegulation

Briefs: Depomed drops Sefelsa after CRL: Sun Pharma stalking Meda?

03-06-2013

US specialty drugmaker Depomed (Nasdaq: DEPO) says that Food and Drug Administration issued a complete…

DepomedMedaMergers & AcquisitionsMetabolicsNorth AmericaPharmaceuticalRegulationResearchSefelsaSun Pharmaceutical Industries

FDA should not approve paroxetine or gabapentin for hot flashes, says Public Citizen

05-03-2013

A drug approved to treat depression and other mental health disorders and another designed to prevent…

DepomedgabapentinHisamitsu PharmaNorth AmericaparoxetinePharmaceuticalRegulationWomen's Health

Depomed says BREEZE 3 data for Serada shows benefits for hot flashes

04-10-2012

USA-based Depomed (Nasdaq: DEPO) is presenting two abstracts from its Phase III clinical trial, BREEZE…

DepomedMetabolicsPharmaceuticalResearchSeradaWomen's Health

Depomed sues FDA over orphan status exclusivity for Gralise

26-09-2012

US drugmaker Depomed (Nasdaq: DEPO) says it has filed an action in federal district court for the District…

DepomedGraliseLegalNeurologicalNorth AmericaPharmaceuticalRare diseases

Depomed files patent infringement suits relating to Gralise

05-03-2012

California, USA-based Depomed (Nasdaq: DEPO) yesterday filed a patent infringement law suit in the US…

ActavisDepomedGenericsGraliseIncepta PharmaceuticalsLegalNeurologicalNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

Back to top